The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated report of a randomized phase III trial comparing 4 and 8 courses of S-1 adjuvant chemotherapy for p-stage II gastric cancer: JCOG1104 (OPAS-1).
 
Masanori Terashima
Honoraria - Chugai Pharma; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Ono Pharmaceutical (Inst)
 
Takaki Yoshikawa
Honoraria - Abbott Nutrition; Ajinomoto; Chugai Pharma; Daiichi Sankyo; Johnson & Johnson; Lilly; Medtronic; Nihonkayaku; Olympus; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Chugai Pharma; MSD Oncology; Novartis
Research Funding - Chugai Pharma; Novartis; Taiho Pharmaceutical; Yakult Pharmaceutical
 
Junki Mizusawa
No Relationships to Disclose
 
Souya Nunobe
No Relationships to Disclose
 
Yasunori Nishida
No Relationships to Disclose
 
Masahide Kaji
No Relationships to Disclose
 
Norimasa Fukushima
No Relationships to Disclose
 
Shinji Hato
No Relationships to Disclose
 
Yasuhiro Choda
No Relationships to Disclose
 
Hiroshi Yabusaki
No Relationships to Disclose
 
Kazuhiro Yoshida
Honoraria - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Covidien; Daiichi Sankyo; Denka Co., Ltd; EA Pharma; Eisai; Johnson & Johnson; Lilly; Merck Serono; MSD K.K; Nippon Kayaku; Olympus; Ono Pharmaceutical; Otsuka; Sanofi; Taiho Pharmaceutical; Takeda; TERUMO; Yakult Honsha
Research Funding - Abbott (Inst); Asahi Kasei (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Johnson & Johnson (Inst); KCI (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Toyama Chemical Co (Inst); Tsumura & Co. (Inst); Yakult Honsha (Inst)
Travel, Accommodations, Expenses - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Covidien; Daiichi Sankyo; Denka Co., Ltd; EA Pharma; Eisai; Johnson & Johnson; Lilly; Merck Serono; MSD K.K; MSD K.K; Nippon Kayaku; Olympus; Ono Pharmaceutical; Otsuka; Sanofi; Taiho Pharmaceutical; Takeda; TERUMO; Yakult Honsha
 
Kazunari Misawa
No Relationships to Disclose
 
Atsushi Takeno
No Relationships to Disclose
 
Masahiro Tsuda
No Relationships to Disclose
 
Yasuyuki Kawachi
No Relationships to Disclose
 
Hiroshi Katayama
Honoraria - Johnson & Johnson
 
Haruhiko Fukuda
Honoraria - Chugai Pharma; Taiho Pharmaceutical
 
Narikazu Boku
Honoraria - Chugai Pharma; Lilly Japan; Merck Serono; Ono Pharmaceutical; Shionogi; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Takeshi Sano
Speakers' Bureau - Chugai Pharma; Johnson & Johnson; Lilly Japan; Medtronic; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Mitsuru Sasako
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Consulting or Advisory Role - Daiichi Sankyo